Lake Street Capital Lowers ReWalk Robotics (NASDAQ:LFWD) Price Target to $4.00

ReWalk Robotics (NASDAQ:LFWD) had its target price reduced by equities researchers at Lake Street Capital from $4.50 to $4.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price target points to a potential upside of 172.11% from the company’s previous close.

LFWD has been the topic of several other reports. Laidlaw initiated coverage on shares of ReWalk Robotics in a report on Monday, February 10th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of ReWalk Robotics in a research report on Tuesday.

ReWalk Robotics Trading Up 1.4 %

NASDAQ:LFWD opened at $1.47 on Tuesday. The stock has a 50 day simple moving average of $1.74 and a 200 day simple moving average of $2.21. The stock has a market cap of $15.62 million, a P/E ratio of -0.59 and a beta of 1.73. ReWalk Robotics has a 1-year low of $1.25 and a 1-year high of $6.00.

ReWalk Robotics (NASDAQ:LFWD) last announced its earnings results on Friday, March 7th. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.53). ReWalk Robotics had a negative return on equity of 43.02% and a negative net margin of 77.21%. The business had revenue of $7.55 million for the quarter, compared to the consensus estimate of $7.30 million. As a group, sell-side analysts forecast that ReWalk Robotics will post -1.78 EPS for the current year.

Insider Transactions at ReWalk Robotics

In other news, major shareholder Global Fund Lp Lind II sold 381,676 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $3.36, for a total value of $1,282,431.36. Following the completion of the sale, the insider now owns 1,049,430 shares in the company, valued at $3,526,084.80. This represents a 26.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.50% of the stock is owned by insiders.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.